Jason Coloma, Maze Therapeutics CEO

Sanofi's next chap­ter in Pompe: $150M for Maze pact as the biotech gears up in CKD

With near­ly $400 mil­lion to its name since Third Rock launched the biotech in 2019, Maze Ther­a­peu­tics has lined up a deal that sees Sanofi snag its Pompe dis­ease pro­gram af­ter tout­ing Phase I da­ta in March and last De­cem­ber.

Sanofi will pay $150 mil­lion in up­front cash and fu­ture eq­ui­ty in the pri­vate biotech and an­oth­er $600 mil­lion could come Maze’s way via biobucks for its oral can­di­date MZE001, back-up pro­grams and IP around its GYS1 pro­gram, the com­pa­nies said Mon­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.